Hope to see some reflection in the PPS now. at 1.5 DYSL is a STRONG STRONG BUY. Hope those analists that ask some questions will start analyse DYSL. That could be the first big gainer for 2015. The rest will follow in 2015. Great things to come. No selling 1 share under 5 dollar here. Will buy more under 2 dollar. glta
NEWTON, Mass., Dec. 16, 2014 /PRNewswire/ -- Dynasil Corporation of America (DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced net income of $2.0 million or $0.13 per common share for the fiscal year ended September 30, 2014 and the filing of its Annual Report on Form 10-K.
"We successfully completed the restructuring of the Company which we started last year," reported Peter Sulick, Chairman and CEO. "During 2014, we sold our lead paint and gamma medical probe businesses, refinanced senior debt which had been in default, reduced our total outstanding debt to $5.6 million from $9.8 million, added needed capacity to our optical coatings business by acquiring DichroTec Thin Films, LLC and returned the Company to profitability. I am particularly excited to report that our four optics business units grew their revenues by 19% in 2014 which substantially offset the revenues associated with the two instrument businesses we sold. In fact, we achieved record revenues at three of our optics business units and saw a substantial increase at the fourth. We believe these business units will continue to generate solid revenue growth in 2015 and beyond."
"We also completed the spin out of our tissue sealant technology to the newly-formed joint venture, Xcede Technologies, and raised $1.4 million of convertible notes from external investors, including officers and directors of the Company, during fiscal year 2014 to fund on-going development of this exciting new technology." Continued Mr. Sulick, "Xcede expects to begin its first in human trials during 2015."
Net income in 2014 was $2.0 million or $0.13 per common share compared to a net loss of $8.7 million or $0.59 per common share in 2013. The net income in 2014 included a $1.3 million gain from the sale of two businesses while the net loss in 2013 included an asset impairment charge of $6.8 million. Excluding the gain on sale in 2014 and the asset impairment charge in 2013, our adjusted net income was $0.8 million in 2014 compared to a loss of $1.9 million in 2013. Our net income in both years was reduced by approximately $0.8 million of losses from our Biomedical segment, which includes the results of the newly formed Xcede Technologies in 2014.
Revenues declined $0.5 million to $42.3 million in 2014 compared to $42.8 million in 2013. Excluding the revenues of the Instruments businesses which were sold in the first quarter of 2014, our adjusted revenues increased 10.3% to $41.5 million in 2014 from $37.6 million in 2013 primarily due to revenue volume growth across all four business units in the Optics segment.
Gross profit for fiscal year 2014 decreased $1.4 million or 7.5% to $16.7 million from the prior year amount of $18.1 million. Gross profit as a percentage of revenue decreased to 39.5% from 42.3% at September 30, 2013 primarily as a result of higher gross profit margins from the Instruments businesses that were sold in the first quarter of fiscal year 2014. Excluding the Instruments businesses, adjusted gross profit increased $0.7 million or 4.8% to $16.4 million in 2014 from $15.7 million in 2013.
Total operating expenses decreased $12.2 million to $14.0 million or 33.2% of revenue in 2014, from $26.2 million in 2013. Total operating expenses included a $1.3 million gain from the sale of the Instruments businesses in 2014 and a $6.8 million asset impairment charge in 2013. Excluding the gain on sale in 2014 and the asset impairment charge in 2013, adjusted total operating expenses decreased $4.1 million primarily as a result of the lower costs resulting from the sale of the Instruments businesses in the first quarter of 2014 and also associated with the Instruments businesses which were sold in the first quarter of fiscal year 2014 as well as cost savings in the Contract Research segment in 2014.
Dynasil's RMD Subsidiary Awarded $3.5 Million in Technology Development Grants by The National Institute of Health. Will this be counted in this Q?
The PPS will follow all the good news we had these last couple of months... and much more to come if we may believe the CEO and we can believe him. I see DYSL surpass 5 dollar in 2015. gltu
Great find... 2015 will be the wake up year for DYSL imo. This will make new Highs in 2015.
The PPS will follow soon. This will not stay under 5 dollar. Glta
What the Hlle are thos MMs doing?
Dynasil Announces Completion of Xcede Technologies' $2 Million Convertible Note Financing
the fact is you are only able to buy shares if you put in a bid order. If you hit the ask the PPS will move up so fast you will only get a few shares. Yesterday at some point there where only 1200 shares between 1.23 and 1.38 on the ask. So if you wanted to buy 1200 shares you would have had to put in an buy order at 1.38 or 12% higher than the PPS. just crazy. If we get good news it will be unable to get in.
don't know i can put the private mail on the internet. you can send me your mail and i will mail it to you. gltu
I've mailed P. Sulick yesterday. Got and very encouraging anwser within an hour.
93800 shares traded in the last 10 trading days... And down almost every single day. Even trades of 1 and 100 shares to paint the price at close of LOD. No volume = easy manipulation. BUY IF YOU CAN!
It was Mr Sulick that pulled me over the line to buy DYSL... He is an example for all CEO's